Cargando…
Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047944/ https://www.ncbi.nlm.nih.gov/pubmed/26542160 http://dx.doi.org/10.1007/s10198-015-0742-5 |
_version_ | 1782457503048531968 |
---|---|
author | Mata-Cases, Manel Casajuana, Marc Franch-Nadal, Josep Casellas, Aina Castell, Conxa Vinagre, Irene Mauricio, Dídac Bolíbar, Bonaventura |
author_facet | Mata-Cases, Manel Casajuana, Marc Franch-Nadal, Josep Casellas, Aina Castell, Conxa Vinagre, Irene Mauricio, Dídac Bolíbar, Bonaventura |
author_sort | Mata-Cases, Manel |
collection | PubMed |
description | We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-015-0742-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5047944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-50479442016-10-18 Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain Mata-Cases, Manel Casajuana, Marc Franch-Nadal, Josep Casellas, Aina Castell, Conxa Vinagre, Irene Mauricio, Dídac Bolíbar, Bonaventura Eur J Health Econ Original Paper We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-015-0742-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-11-05 2016 /pmc/articles/PMC5047944/ /pubmed/26542160 http://dx.doi.org/10.1007/s10198-015-0742-5 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Mata-Cases, Manel Casajuana, Marc Franch-Nadal, Josep Casellas, Aina Castell, Conxa Vinagre, Irene Mauricio, Dídac Bolíbar, Bonaventura Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title | Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title_full | Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title_fullStr | Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title_full_unstemmed | Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title_short | Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain |
title_sort | direct medical costs attributable to type 2 diabetes mellitus: a population-based study in catalonia, spain |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047944/ https://www.ncbi.nlm.nih.gov/pubmed/26542160 http://dx.doi.org/10.1007/s10198-015-0742-5 |
work_keys_str_mv | AT matacasesmanel directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT casajuanamarc directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT franchnadaljosep directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT casellasaina directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT castellconxa directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT vinagreirene directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT mauriciodidac directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain AT bolibarbonaventura directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain |